Saturday 17 October 2026 Export ORGS’s income statement to Excel — free account

Orgenesis Inc.

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.

0.06 0.06 Infinity

Follow ORGS

Alert me

Market cap: $5.7M
P/E: 0.0×
Fwd P/E: 1.0×
Dividend yield: —
F-score: 3/9
Altman Z: −352.42
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 5.68

Revenue 1.04

Net Income (49.01)

Free Cash Flow (17.34)

Net Debt 16.01

Current Ratio 0.03

Debt/Equity (0.44)

P/E ratio 0.00

Fwd P/E 1.02

P/S ratio 0.24

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 13,164.15%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.14%

10-year low 10-year high

EV/Sales against its own 10 years 71.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	2024
Cash	6	6	1	1
Receivables	15	36	1	0
Inventory	0	0	0	—
Other	3	3	—	—
	26	46	4	1

	2021	2022	2023	2024
Payables	5	4	7	13
ST’ Debt	6	5	3	8
Other	0	—	—	—
	15	16	16	27

Compound Annual Growth %

	10y	5y	3y
Sales	(16.65%)	(23.30%)	(69.22%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	0	0	0	0	1
’23	0	0	0	0	1
’22	7	7	8	14	36
’21	9	11	9	7	36
’20	2	2	2	2	8
’19	0	1	1	1	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	(4)	(6)	(5)	(2)	(17)
’23	(7)	(6)	(1)	(1)	(15)
’22	(3)	(6)	(5)	(11)	(25)
’21	(5)	(11)	(8)	(2)	(27)
’20	(14)	(9)	(10)	(45)	(78)
’19	(5)	(4)	(2)	(3)	(13)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	(5)	(6)	(5)	(2)	(17)
’23	(9)	(6)	(1)	(1)	(17)
’22	(4)	(10)	(8)	(16)	(37)
’21	(5)	(13)	(10)	(7)	(35)
’20	(14)	(9)	(10)	(45)	(80)
’19	(5)	(5)	(6)	(9)	(25)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	(2.90)	(2.30)	(1.93)	(4.38)	(11.44)
’23	(8.83)	(1.50)	(1.24)	(1.40)	(19.10)
’22	1.62	2.21	0.55	(9.24)	(5.90)
’21	(0.10)	(1.12)	(4.18)	(2.00)	(7.40)
’20	42.30	9.50	(1.10)	(28.20)	2.90
’19	5.50	3.60	4.40	(4.20)	(17.70)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	28.22	27.60	38.70	23.50	27.60	25.60	11.30	3.84	0.87	Analyst estimates 2025–2027 Powerpack
	High	—	61.80	117.60	168.00	59.28	82.00	83.00	40.40	26.40	10.80
People
People	Employees	—	80	103	231	309	111	151	167	146	77
	Revenue/emp, $m	—	0.00	0.00	0.00	0.01	0.07	0.24	0.22	0.00	0.01
Income, $m
Income, $m	Revenue	—	6	10	21	4	8	36	36	1	1
	Gross margin, %	—	(45.02)	15.27	41.26	(259.43)	(997.57)	(3.22)	85.75	(1,080.19)	(86.28)
	EBT	—	(13)	(14)	(21)	(23)	(97)	(18)	(12)	(64)	(49)
	EBT margin, %	—	(197.91)	(135.56)	(101.22)	(585.23)	(1,264.19)	(50.56)	(33.20)	(12,159.43)	(4,726.18)
	Net income	—	(11)	(12)	(22)	(26)	1	(18)	(12)	(65)	(49)
	Depreciation	—	3	3	3	4	1	2	2	2	2
Per share, $
Per share, $	Revenue	—	0.75	1.04	15.33	2.45	3.59	14.63	14.35	0.18	0.25
	Earnings	—	(1.30)	(1.31)	(14.30)	(17.70)	2.90	(7.40)	(5.90)	(19.10)	(11.44)
	Cash flow	—	(0.44)	(0.40)	(12.53)	(8.31)	(36.61)	(11.07)	(9.93)	(5.11)	(4.06)
	Capex	—	0.00	0.00	(4.55)	(7.57)	(0.71)	(3.24)	(4.85)	(0.72)	(0.06)
	Free cash flow	—	(0.44)	(0.40)	(17.09)	(15.89)	(37.32)	(14.31)	(14.78)	(5.84)	(4.12)
	Book value	—	1.47	1.46	20.00	3.82	24.73	15.91	11.58	(7.23)	(8.91)
	Shares, m	—	9	10	1	2	2	2	3	3	4
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	5.01	2.00	0.00	0.00	0.00	0.00
	P/S	—	5.95	6.31	3.05	19.01	12.54	1.97	1.37	26.93	7.69
	P/B	—	4.10	3.83	2.34	12.20	1.82	1.81	1.69	0.00	0.00
	EV/Sales	—	7.46	6.81	2.54	22.19	8.07	2.10	1.69	66.20	23.15
	EV/FCF	—	8.68	26.10	(2.28)	(3.42)	(0.78)	(2.15)	(1.64)	(2.07)	(1.38)
Cash, $m
Cash, $m	Operating cash flow	—	(4)	(4)	(17)	(13)	(78)	(27)	(25)	(15)	(17)
	Capex	—	(1)	(1)	(6)	(12)	(2)	(8)	(12)	(2)	0
	Free cash flow	—	(4)	(4)	(23)	(25)	(80)	(35)	(37)	(17)	(17)
Balance, $m
Balance, $m	Working capital	—	(10)	(10)	11	36	34	10	30	(12)	(26)
	Total debt	—	10	8	5	13	11	11	18	22	17
	Net debt	—	9	4	(10)	12	(34)	5	12	21	16
	Shareholders’ equity	—	12	14	27	6	53	39	29	(21)	(38)
Returns, %
Returns, %	ROA	—	(33.19)	(31.02)	(29.60)	(29.00)	1.30	(26.25)	(19.75)	(104.97)	(605.73)
	ROIC	—	0.00	0.00	(64.80)	(74.42)	(322.83)	(24.17)	(15.55)	0.00	0.00
	ROE	—	(88.93)	(87.57)	(79.78)	(146.95)	3.78	(39.52)	(43.98)	(1,368.97)	164.62

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TRAW Traws Pharma, Inc.	$6.2M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−25.51% (below 0%: shrinking)	0.00%	0.00%	Compare
ALZN Alzamend Neuro, Inc.	$6.2M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
NRSN NeuroSense Therapeutics Ltd.	$6.0M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
IMNN Imunon, Inc.	$6.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−4.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ORGS Orgenesis Inc.	$5.7M	— (loss-making)	1.0×	+82.42% (above 0%: growing)	n/m	−317.93% (below 0%: shrinking)	2,780.73%	(6,044.52%)
CANF Can-Fite Biopharma Ltd	$5.6M	— (loss-making)	— (loss-making)	−1.18% (below 0%: shrinking)	n/m	+12.63% (above 0%: growing)	0.00%	0.00%	Compare
BGMS Bio Green Med Solution, Inc.	$5.5M	— (loss-making)	— (loss-making)	+3,260.00% (above 0%: growing)	n/m	+66.67% (above 0%: growing)	23.51%	(124.40%)	Compare
CELZ Creative Medical Technology Holdings, Inc.	$5.4M	— (loss-making)	— (loss-making)	0.00%	n/m	−27.05% (below 0%: shrinking)	66.67%	0.00%	Compare
CDIO Cardio Diagnostics Holdings, Inc.	$5.2M	— (loss-making)	— (loss-making)	−28.00% (below 0%: shrinking)	n/m	+15.58% (above 0%: growing)	100.00%	(27,742.59%)	Compare
Median of peers	$5.8M	—	—	−0.59%	—	+4.20%	0.00%	0.00%

All 614 Biotechnology stocks →

Orgenesis Inc. (ORGS) key facts

Strength: Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023.
Orgenesis Inc. (ORGS) is a Biotechnology company in the Healthcare sector.
As of October 15, 2026, ORGS traded at $0.06, a market capitalization of $5.7 million.
Return on equity was 164.6% and debt-to-equity -0.44.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −352.42 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.